Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on November 1, 2023, covering events occurring on October 30, 2023. The filing primarily addresses the appointment of a new Chief Financial Officer and Chief Business Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer, effective November 6, 2023. She succeeds Stephen DiPalma, who served as Interim Chief Financial Officer. Ms. Rajavelu will formally assume the CFO role after the filing of the Company's Form 10-Q for the quarter ended September 30, 2023.
Management Commentary, Risks, and Unusual Items
Compensation and Equity Grant:
- Base Salary: $475,000 annually.
- Sign-on Bonus: $50,000 one-time payment.
- Annual Performance Bonus: Up to 40% of base salary, commencing in fiscal year 2024.
- Equity Grant: 300,000 Restricted Stock Units (RSUs) granted on November 13, 2023, vesting in four equal annual installments.
- Standard Termination (Without Cause/Good Reason): Nine months of base salary, pro-rated target bonus, and continued health insurance coverage (up to 12 months).
- Change of Control Termination: 12 months of base salary plus target bonus, acceleration of all unvested equity awards, and continued health insurance coverage (up to 12 months).
The filing notes that the RSU grant is structured as an inducement material to Ms. Rajavelu's employment to comply with Nasdaq Listing Rule 5635(c)(4). No other specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the exact date Ms. Rajavelu formally assumes the CFO title relative to the upcoming 10-Q filing.
- Review the full text of the executive employment agreement (to be filed as an exhibit to the 2023 Form 10-K) for detailed definitions of "Cause" and "Good Reason."
- Confirm the impact of the 300,000 RSU grant on total share count and dilution.
- Monitor the transition period to ensure continuity in financial reporting and investor relations.